Showing 3061-3070 of 9123 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0909_05-php/22769/First Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates.The Landscape of Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/the-landscape-of-vitiligo-treatment/24467/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Lawrence Green, MD, a dermatologist practicing in Rockville, MD, about the landscape of treatments for patients with vitiligo and new therapies that may be coming from ongoing clinical trials.New Clinical Guidelines for Nonmelanoma Skin Cancer Treatment; Arctics Biotherapeutics Seeks New FDA Approval for ZORYVE Foam
https://practicaldermatology.com/series/dermwire-tv/new-clinical-guidelines-for-nonmelanoma-skin-cancer-treatment-arctics-biotherapeutics-seeks-new-fda-approval-for-zoryve-foam/26745/In this week’s DermwireTV, new clinical guidelines for nonmelanoma skin cancer treatment; Arcutis Biotherapeutics seeks new FDA approval for ZORYVE foam; Practical Dermatology joins the ReachMD network; and the CEO of SofWave Medical joins us to discuss the company’s Ultrasound technology.Journal Club: Combining Dupilumab and Omalizumab
https://reachmd.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-combining-dupilumab-and-omalizumab/37872/Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, and editorial board member Brad Glick, DO, MPH, FAAD, discuss a recent article about combination therapy with dupilumab and omalizumab for atopic dermatitis. Silva IC, Daher R, Khattri S. Combined use of Omalizumab and dupilumabJournal Club: Comparing Recommendations from Different AD Guidelines
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-comparing-recommendations-from-different-ad-guidelines/24466/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a pediatric dermatologist at Seattle Children's Hospital, about some of the differences in recommendations from the Annals of Allergy, Asthma, and Immunology Joint Task Force AD guidelines, and the Journal of the American Academy of Dermatology (JAAJournal Club: Efficacy of Systemics After Discontinuation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-efficacy-of-systemics-after-discontinuation/32829/Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, is joined by Naiem T. Issa, MD, PhD, to discuss an article Dr. Issa authored reviewing published literature on the efficacy of biologics as monotherapy for atopic dermatitis following discontinuation. Issa NT, Abdin R, et al.Clinical Data on Switching to Upadacitinib
https://practicaldermatology.com/series/updates-atopic-dermatitis/clinical-data-on-switching-to-upadacitinib/36534/Clinical investigator Christopher Bunick, MD, PhD, discusses results from the LEVEL UP trial among patients who switched from dupilumab to upadacitinib for atopic dermatitis.The Future of Atopic Dermatitis Therapy
https://practicaldermatology.com/topics/general-topics/the-future-of-atopic-dermatitis-therapy/21143/As new research elucidates the individual mechanisms of atopic dermatitis, the development of therapies that more directly influence the disease may change the scope of treatment.New Drugs for Treating Fungal Infections
https://practicaldermatology.com/topics/general-topics/new-drugs-for-treating-fungal-infections/21426/A review of recent developments for efficacious treatment.